nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—TYK2—psoriasis	0.641	1	CbGaD
Ruxolitinib—BMP2K—synovial membrane of synovial joint—psoriasis	0.0063	0.141	CbGeAlD
Ruxolitinib—PLK1—skin of body—psoriasis	0.00261	0.0584	CbGeAlD
Ruxolitinib—PRKCE—tendon—psoriasis	0.00207	0.0463	CbGeAlD
Ruxolitinib—RPS6KA6—tendon—psoriasis	0.00199	0.0444	CbGeAlD
Ruxolitinib—JAK1—skin of body—psoriasis	0.00167	0.0374	CbGeAlD
Ruxolitinib—PLK1—Mycophenolate mofetil—Mycophenolic acid—psoriasis	0.00161	0.333	CbGdCrCtD
Ruxolitinib—CAMK1—tendon—psoriasis	0.00155	0.0347	CbGeAlD
Ruxolitinib—MARK2—tendon—psoriasis	0.00151	0.0337	CbGeAlD
Ruxolitinib—BMPR2—skin of body—psoriasis	0.0014	0.0313	CbGeAlD
Ruxolitinib—TAOK2—tendon—psoriasis	0.00139	0.0312	CbGeAlD
Ruxolitinib—DYRK1A—Mycophenolic acid—Mycophenolate mofetil—psoriasis	0.00133	0.275	CbGdCrCtD
Ruxolitinib—JAK1—tendon—psoriasis	0.00127	0.0285	CbGeAlD
Ruxolitinib—DCLK1—tendon—psoriasis	0.00127	0.0285	CbGeAlD
Ruxolitinib—CAMK1D—tendon—psoriasis	0.00124	0.0278	CbGeAlD
Ruxolitinib—PHKG2—tendon—psoriasis	0.00124	0.0276	CbGeAlD
Ruxolitinib—DAPK2—tendon—psoriasis	0.00121	0.0272	CbGeAlD
Ruxolitinib—STK16—tendon—psoriasis	0.0012	0.0267	CbGeAlD
Ruxolitinib—HIPK2—tendon—psoriasis	0.00119	0.0266	CbGeAlD
Ruxolitinib—DAPK3—tendon—psoriasis	0.00114	0.0255	CbGeAlD
Ruxolitinib—CLK2—tendon—psoriasis	0.00113	0.0253	CbGeAlD
Ruxolitinib—TYK2—skin of body—psoriasis	0.00111	0.0247	CbGeAlD
Ruxolitinib—BMPR2—tendon—psoriasis	0.00107	0.0238	CbGeAlD
Ruxolitinib—JAK2—skin of body—psoriasis	0.00101	0.0225	CbGeAlD
Ruxolitinib—MAP3K3—skin of body—psoriasis	0.00097	0.0217	CbGeAlD
Ruxolitinib—CAMK2G—tendon—psoriasis	0.000953	0.0213	CbGeAlD
Ruxolitinib—BMP2K—tendon—psoriasis	0.000953	0.0213	CbGeAlD
Ruxolitinib—LRRK2—tendon—psoriasis	0.000945	0.0211	CbGeAlD
Ruxolitinib—PLK1—Mycophenolic acid—Mycophenolate mofetil—psoriasis	0.000911	0.188	CbGdCrCtD
Ruxolitinib—MAP3K7—tendon—psoriasis	0.000857	0.0192	CbGeAlD
Ruxolitinib—TYK2—tendon—psoriasis	0.000842	0.0188	CbGeAlD
Ruxolitinib—IRAK1—tendon—psoriasis	0.000831	0.0186	CbGeAlD
Ruxolitinib—MKNK2—tendon—psoriasis	0.000831	0.0186	CbGeAlD
Ruxolitinib—RET—tendon—psoriasis	0.000811	0.0181	CbGeAlD
Ruxolitinib—JAK2—tendon—psoriasis	0.000766	0.0171	CbGeAlD
Ruxolitinib—MAP3K3—tendon—psoriasis	0.000738	0.0165	CbGeAlD
Ruxolitinib—TAOK3—tendon—psoriasis	0.000673	0.015	CbGeAlD
Ruxolitinib—Haemoglobin—Acitretin—psoriasis	0.000572	0.00507	CcSEcCtD
Ruxolitinib—Haemorrhage—Acitretin—psoriasis	0.00057	0.00505	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Mycophenolic acid—psoriasis	0.000541	0.0048	CcSEcCtD
Ruxolitinib—PLK1—Calcipotriol—Calcitriol—psoriasis	0.000535	0.11	CbGdCrCtD
Ruxolitinib—Pancytopenia—Hydroxyurea—psoriasis	0.000531	0.0047	CcSEcCtD
Ruxolitinib—Contusion—Dexamethasone—psoriasis	0.000525	0.00465	CcSEcCtD
Ruxolitinib—Contusion—Betamethasone—psoriasis	0.000525	0.00465	CcSEcCtD
Ruxolitinib—Neutropenia—Hydroxyurea—psoriasis	0.000522	0.00463	CcSEcCtD
Ruxolitinib—Weight increased—Hydroxyurea—psoriasis	0.000508	0.00451	CcSEcCtD
Ruxolitinib—Pruritus—Clobetasol propionate—psoriasis	0.000507	0.0045	CcSEcCtD
Ruxolitinib—Infection—Methoxsalen—psoriasis	0.000507	0.00449	CcSEcCtD
Ruxolitinib—Infestation NOS—Hydroxyurea—psoriasis	0.000498	0.00442	CcSEcCtD
Ruxolitinib—Infestation—Hydroxyurea—psoriasis	0.000498	0.00442	CcSEcCtD
Ruxolitinib—Skin disorder—Methoxsalen—psoriasis	0.000496	0.00439	CcSEcCtD
Ruxolitinib—Malnutrition—Fluocinolone Acetonide—psoriasis	0.000494	0.00438	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Mycophenolic acid—psoriasis	0.000477	0.00423	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Hydroxyurea—psoriasis	0.000471	0.00418	CcSEcCtD
Ruxolitinib—Pruritus—Fluocinonide—psoriasis	0.000457	0.00405	CcSEcCtD
Ruxolitinib—Contusion—Prednisone—psoriasis	0.000457	0.00405	CcSEcCtD
Ruxolitinib—PLK1—Calcipotriol—Cholecalciferol—psoriasis	0.000455	0.0938	CbGdCrCtD
Ruxolitinib—Haemoglobin—Hydroxyurea—psoriasis	0.000449	0.00398	CcSEcCtD
Ruxolitinib—Headache—Clobetasol propionate—psoriasis	0.000449	0.00398	CcSEcCtD
Ruxolitinib—Haemorrhage—Hydroxyurea—psoriasis	0.000447	0.00396	CcSEcCtD
Ruxolitinib—Pancytopenia—Mycophenolic acid—psoriasis	0.000444	0.00394	CcSEcCtD
Ruxolitinib—Herpes zoster—Methotrexate—psoriasis	0.000443	0.00392	CcSEcCtD
Ruxolitinib—Skin disorder—Calcitriol—psoriasis	0.000442	0.00392	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Methoxsalen—psoriasis	0.000441	0.00391	CcSEcCtD
Ruxolitinib—Neutropenia—Mycophenolic acid—psoriasis	0.000438	0.00388	CcSEcCtD
Ruxolitinib—Dizziness—Beclomethasone—psoriasis	0.000432	0.00382	CcSEcCtD
Ruxolitinib—Dizziness—Fluocinonide—psoriasis	0.000428	0.00379	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Mycophenolate mofetil—psoriasis	0.000427	0.00379	CcSEcCtD
Ruxolitinib—Weight increased—Mycophenolic acid—psoriasis	0.000426	0.00377	CcSEcCtD
Ruxolitinib—Weight decreased—Mycophenolic acid—psoriasis	0.000423	0.00375	CcSEcCtD
Ruxolitinib—Hypercholesterolaemia—Prednisone—psoriasis	0.000422	0.00374	CcSEcCtD
Ruxolitinib—Infestation NOS—Mycophenolic acid—psoriasis	0.000417	0.0037	CcSEcCtD
Ruxolitinib—Infestation—Mycophenolic acid—psoriasis	0.000417	0.0037	CcSEcCtD
Ruxolitinib—Headache—Beclomethasone—psoriasis	0.000409	0.00362	CcSEcCtD
Ruxolitinib—Urinary tract infection—Mycophenolic acid—psoriasis	0.000406	0.00359	CcSEcCtD
Ruxolitinib—Headache—Fluocinonide—psoriasis	0.000405	0.00359	CcSEcCtD
Ruxolitinib—Body temperature increased—Methoxsalen—psoriasis	0.000403	0.00358	CcSEcCtD
Ruxolitinib—Infection—Acitretin—psoriasis	0.000402	0.00356	CcSEcCtD
Ruxolitinib—Infection—Fluocinolone Acetonide—psoriasis	0.000401	0.00355	CcSEcCtD
Ruxolitinib—Haematuria—Mycophenolic acid—psoriasis	0.000398	0.00353	CcSEcCtD
Ruxolitinib—Nervous system disorder—Fluocinolone Acetonide—psoriasis	0.000396	0.00351	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Mycophenolic acid—psoriasis	0.000395	0.0035	CcSEcCtD
Ruxolitinib—Epistaxis—Mycophenolic acid—psoriasis	0.000393	0.00349	CcSEcCtD
Ruxolitinib—Skin disorder—Acitretin—psoriasis	0.000393	0.00348	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Mycophenolate mofetil—psoriasis	0.000377	0.00334	CcSEcCtD
Ruxolitinib—Haemoglobin—Mycophenolic acid—psoriasis	0.000376	0.00334	CcSEcCtD
Ruxolitinib—Haemorrhage—Mycophenolic acid—psoriasis	0.000375	0.00332	CcSEcCtD
Ruxolitinib—Pruritus—Methoxsalen—psoriasis	0.000361	0.0032	CcSEcCtD
Ruxolitinib—Anaemia—Hydroxyurea—psoriasis	0.00036	0.00319	CcSEcCtD
Ruxolitinib—Body temperature increased—Calcitriol—psoriasis	0.00036	0.00319	CcSEcCtD
Ruxolitinib—Pancytopenia—Mycophenolate mofetil—psoriasis	0.000351	0.00311	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Acitretin—psoriasis	0.000349	0.0031	CcSEcCtD
Ruxolitinib—Fatigue—Acitretin—psoriasis	0.000349	0.00309	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Fluocinolone Acetonide—psoriasis	0.000348	0.00309	CcSEcCtD
Ruxolitinib—Neutropenia—Mycophenolate mofetil—psoriasis	0.000345	0.00306	CcSEcCtD
Ruxolitinib—Weight increased—Cyclosporine—psoriasis	0.000344	0.00305	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Hydrocortisone—psoriasis	0.000343	0.00304	CcSEcCtD
Ruxolitinib—Weight decreased—Cyclosporine—psoriasis	0.000342	0.00304	CcSEcCtD
Ruxolitinib—Infestation—Cyclosporine—psoriasis	0.000338	0.00299	CcSEcCtD
Ruxolitinib—Infestation NOS—Cyclosporine—psoriasis	0.000338	0.00299	CcSEcCtD
Ruxolitinib—Dizziness—Methoxsalen—psoriasis	0.000337	0.00299	CcSEcCtD
Ruxolitinib—Weight increased—Mycophenolate mofetil—psoriasis	0.000336	0.00298	CcSEcCtD
Ruxolitinib—Weight decreased—Mycophenolate mofetil—psoriasis	0.000334	0.00296	CcSEcCtD
Ruxolitinib—Infestation NOS—Mycophenolate mofetil—psoriasis	0.000329	0.00292	CcSEcCtD
Ruxolitinib—Infestation—Mycophenolate mofetil—psoriasis	0.000329	0.00292	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—psoriasis	0.000329	0.00292	CcSEcCtD
Ruxolitinib—Urinary tract infection—Cyclosporine—psoriasis	0.000328	0.00291	CcSEcCtD
Ruxolitinib—Asthenia—Calcitriol—psoriasis	0.000326	0.00289	CcSEcCtD
Ruxolitinib—Malnutrition—Mycophenolic acid—psoriasis	0.000326	0.00289	CcSEcCtD
Ruxolitinib—Pruritus—Calcitriol—psoriasis	0.000322	0.00285	CcSEcCtD
Ruxolitinib—Haematuria—Cyclosporine—psoriasis	0.000322	0.00285	CcSEcCtD
Ruxolitinib—Flatulence—Mycophenolic acid—psoriasis	0.000321	0.00285	CcSEcCtD
Ruxolitinib—Urinary tract infection—Mycophenolate mofetil—psoriasis	0.00032	0.00284	CcSEcCtD
Ruxolitinib—Body temperature increased—Acitretin—psoriasis	0.00032	0.00284	CcSEcCtD
Ruxolitinib—Headache—Methoxsalen—psoriasis	0.00032	0.00283	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Cyclosporine—psoriasis	0.000319	0.00283	CcSEcCtD
Ruxolitinib—Body temperature increased—Fluocinolone Acetonide—psoriasis	0.000319	0.00283	CcSEcCtD
Ruxolitinib—Epistaxis—Cyclosporine—psoriasis	0.000318	0.00282	CcSEcCtD
Ruxolitinib—Infection—Hydroxyurea—psoriasis	0.000316	0.0028	CcSEcCtD
Ruxolitinib—Haematuria—Mycophenolate mofetil—psoriasis	0.000314	0.00278	CcSEcCtD
Ruxolitinib—Weight increased—Prednisolone—psoriasis	0.000313	0.00278	CcSEcCtD
Ruxolitinib—Nervous system disorder—Hydroxyurea—psoriasis	0.000312	0.00276	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Mycophenolate mofetil—psoriasis	0.000311	0.00276	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Hydroxyurea—psoriasis	0.000311	0.00276	CcSEcCtD
Ruxolitinib—Epistaxis—Mycophenolate mofetil—psoriasis	0.000311	0.00275	CcSEcCtD
Ruxolitinib—Skin disorder—Hydroxyurea—psoriasis	0.000309	0.00274	CcSEcCtD
Ruxolitinib—Weight increased—Hydrocortisone—psoriasis	0.000306	0.00271	CcSEcCtD
Ruxolitinib—Haemoglobin—Cyclosporine—psoriasis	0.000305	0.0027	CcSEcCtD
Ruxolitinib—Weight decreased—Hydrocortisone—psoriasis	0.000304	0.0027	CcSEcCtD
Ruxolitinib—Haemorrhage—Cyclosporine—psoriasis	0.000303	0.00269	CcSEcCtD
Ruxolitinib—Anaemia—Mycophenolic acid—psoriasis	0.000301	0.00267	CcSEcCtD
Ruxolitinib—Infestation—Hydrocortisone—psoriasis	0.0003	0.00266	CcSEcCtD
Ruxolitinib—Infestation NOS—Hydrocortisone—psoriasis	0.0003	0.00266	CcSEcCtD
Ruxolitinib—Haemoglobin—Mycophenolate mofetil—psoriasis	0.000297	0.00263	CcSEcCtD
Ruxolitinib—Haemorrhage—Mycophenolate mofetil—psoriasis	0.000296	0.00262	CcSEcCtD
Ruxolitinib—Asthenia—Acitretin—psoriasis	0.00029	0.00257	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Prednisone—psoriasis	0.00029	0.00257	CcSEcCtD
Ruxolitinib—Weight increased—Triamcinolone—psoriasis	0.000288	0.00256	CcSEcCtD
Ruxolitinib—Pruritus—Acitretin—psoriasis	0.000286	0.00254	CcSEcCtD
Ruxolitinib—Pruritus—Fluocinolone Acetonide—psoriasis	0.000285	0.00253	CcSEcCtD
Ruxolitinib—Headache—Calcitriol—psoriasis	0.000285	0.00253	CcSEcCtD
Ruxolitinib—Haemoglobin—Prednisolone—psoriasis	0.000277	0.00246	CcSEcCtD
Ruxolitinib—Haemorrhage—Prednisolone—psoriasis	0.000276	0.00244	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—psoriasis	0.000276	0.00244	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.000274	0.00243	CcSEcCtD
Ruxolitinib—Fatigue—Hydroxyurea—psoriasis	0.000274	0.00243	CcSEcCtD
Ruxolitinib—Haemoglobin—Hydrocortisone—psoriasis	0.000271	0.0024	CcSEcCtD
Ruxolitinib—Haemorrhage—Hydrocortisone—psoriasis	0.000269	0.00239	CcSEcCtD
Ruxolitinib—Dizziness—Acitretin—psoriasis	0.000268	0.00237	CcSEcCtD
Ruxolitinib—Dizziness—Fluocinolone Acetonide—psoriasis	0.000267	0.00237	CcSEcCtD
Ruxolitinib—Epistaxis—Triamcinolone—psoriasis	0.000266	0.00236	CcSEcCtD
Ruxolitinib—Infection—Mycophenolic acid—psoriasis	0.000264	0.00234	CcSEcCtD
Ruxolitinib—Malnutrition—Cyclosporine—psoriasis	0.000264	0.00234	CcSEcCtD
Ruxolitinib—Weight increased—Dexamethasone—psoriasis	0.000262	0.00232	CcSEcCtD
Ruxolitinib—Weight increased—Betamethasone—psoriasis	0.000262	0.00232	CcSEcCtD
Ruxolitinib—Nervous system disorder—Mycophenolic acid—psoriasis	0.000261	0.00231	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Mycophenolic acid—psoriasis	0.000261	0.00231	CcSEcCtD
Ruxolitinib—Weight decreased—Betamethasone—psoriasis	0.00026	0.0023	CcSEcCtD
Ruxolitinib—Weight decreased—Dexamethasone—psoriasis	0.00026	0.0023	CcSEcCtD
Ruxolitinib—Flatulence—Cyclosporine—psoriasis	0.00026	0.0023	CcSEcCtD
Ruxolitinib—Skin disorder—Mycophenolic acid—psoriasis	0.000258	0.00229	CcSEcCtD
Ruxolitinib—Malnutrition—Mycophenolate mofetil—psoriasis	0.000257	0.00228	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Prednisone—psoriasis	0.000255	0.00226	CcSEcCtD
Ruxolitinib—Haemoglobin—Triamcinolone—psoriasis	0.000255	0.00226	CcSEcCtD
Ruxolitinib—Haemorrhage—Triamcinolone—psoriasis	0.000254	0.00225	CcSEcCtD
Ruxolitinib—Flatulence—Mycophenolate mofetil—psoriasis	0.000254	0.00225	CcSEcCtD
Ruxolitinib—Headache—Acitretin—psoriasis	0.000253	0.00225	CcSEcCtD
Ruxolitinib—Headache—Fluocinolone Acetonide—psoriasis	0.000253	0.00224	CcSEcCtD
Ruxolitinib—Body temperature increased—Hydroxyurea—psoriasis	0.000251	0.00223	CcSEcCtD
Ruxolitinib—Anaemia—Cyclosporine—psoriasis	0.000244	0.00216	CcSEcCtD
Ruxolitinib—Anaemia—Mycophenolate mofetil—psoriasis	0.000238	0.00211	CcSEcCtD
Ruxolitinib—Malnutrition—Hydrocortisone—psoriasis	0.000234	0.00208	CcSEcCtD
Ruxolitinib—Neutropenia—Prednisone—psoriasis	0.000234	0.00207	CcSEcCtD
Ruxolitinib—Haemoglobin—Dexamethasone—psoriasis	0.000231	0.00205	CcSEcCtD
Ruxolitinib—Haemoglobin—Betamethasone—psoriasis	0.000231	0.00205	CcSEcCtD
Ruxolitinib—Haemorrhage—Dexamethasone—psoriasis	0.00023	0.00204	CcSEcCtD
Ruxolitinib—Haemorrhage—Betamethasone—psoriasis	0.00023	0.00204	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.00023	0.00204	CcSEcCtD
Ruxolitinib—Fatigue—Mycophenolic acid—psoriasis	0.000229	0.00203	CcSEcCtD
Ruxolitinib—Asthenia—Hydroxyurea—psoriasis	0.000228	0.00202	CcSEcCtD
Ruxolitinib—Weight increased—Prednisone—psoriasis	0.000228	0.00202	CcSEcCtD
Ruxolitinib—Weight decreased—Prednisone—psoriasis	0.000226	0.00201	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.000223	0.00198	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.000218	0.00193	CcSEcCtD
Ruxolitinib—Infection—Cyclosporine—psoriasis	0.000214	0.0019	CcSEcCtD
Ruxolitinib—Nervous system disorder—Cyclosporine—psoriasis	0.000211	0.00187	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Cyclosporine—psoriasis	0.000211	0.00187	CcSEcCtD
Ruxolitinib—Body temperature increased—Mycophenolic acid—psoriasis	0.00021	0.00186	CcSEcCtD
Ruxolitinib—Dizziness—Hydroxyurea—psoriasis	0.00021	0.00186	CcSEcCtD
Ruxolitinib—Skin disorder—Cyclosporine—psoriasis	0.000209	0.00185	CcSEcCtD
Ruxolitinib—Infection—Mycophenolate mofetil—psoriasis	0.000209	0.00185	CcSEcCtD
Ruxolitinib—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000206	0.00183	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.000206	0.00182	CcSEcCtD
Ruxolitinib—Skin disorder—Mycophenolate mofetil—psoriasis	0.000204	0.00181	CcSEcCtD
Ruxolitinib—Haemoglobin—Prednisone—psoriasis	0.000201	0.00178	CcSEcCtD
Ruxolitinib—Haemorrhage—Prednisone—psoriasis	0.0002	0.00178	CcSEcCtD
Ruxolitinib—Headache—Hydroxyurea—psoriasis	0.000199	0.00176	CcSEcCtD
Ruxolitinib—Pancytopenia—Methotrexate—psoriasis	0.000199	0.00176	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000198	0.00176	CcSEcCtD
Ruxolitinib—Neutropenia—Methotrexate—psoriasis	0.000196	0.00173	CcSEcCtD
Ruxolitinib—Asthenia—Mycophenolic acid—psoriasis	0.000191	0.00169	CcSEcCtD
Ruxolitinib—Infection—Hydrocortisone—psoriasis	0.00019	0.00168	CcSEcCtD
Ruxolitinib—Pruritus—Mycophenolic acid—psoriasis	0.000188	0.00167	CcSEcCtD
Ruxolitinib—Nervous system disorder—Hydrocortisone—psoriasis	0.000188	0.00166	CcSEcCtD
Ruxolitinib—Infestation NOS—Methotrexate—psoriasis	0.000187	0.00165	CcSEcCtD
Ruxolitinib—Infestation—Methotrexate—psoriasis	0.000187	0.00165	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000186	0.00165	CcSEcCtD
Ruxolitinib—Skin disorder—Hydrocortisone—psoriasis	0.000186	0.00165	CcSEcCtD
Ruxolitinib—Fatigue—Cyclosporine—psoriasis	0.000186	0.00164	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000181	0.00161	CcSEcCtD
Ruxolitinib—Infection—Triamcinolone—psoriasis	0.000179	0.00159	CcSEcCtD
Ruxolitinib—Haematuria—Methotrexate—psoriasis	0.000178	0.00158	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Methotrexate—psoriasis	0.000176	0.00156	CcSEcCtD
Ruxolitinib—Dizziness—Mycophenolic acid—psoriasis	0.000176	0.00156	CcSEcCtD
Ruxolitinib—Epistaxis—Methotrexate—psoriasis	0.000176	0.00156	CcSEcCtD
Ruxolitinib—Malnutrition—Prednisone—psoriasis	0.000174	0.00155	CcSEcCtD
Ruxolitinib—Body temperature increased—Cyclosporine—psoriasis	0.00017	0.00151	CcSEcCtD
Ruxolitinib—Haemoglobin—Methotrexate—psoriasis	0.000168	0.00149	CcSEcCtD
Ruxolitinib—Haemorrhage—Methotrexate—psoriasis	0.000167	0.00148	CcSEcCtD
Ruxolitinib—Headache—Mycophenolic acid—psoriasis	0.000167	0.00148	CcSEcCtD
Ruxolitinib—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000166	0.00147	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000165	0.00146	CcSEcCtD
Ruxolitinib—Fatigue—Hydrocortisone—psoriasis	0.000165	0.00146	CcSEcCtD
Ruxolitinib—Infection—Betamethasone—psoriasis	0.000162	0.00144	CcSEcCtD
Ruxolitinib—Infection—Dexamethasone—psoriasis	0.000162	0.00144	CcSEcCtD
Ruxolitinib—Anaemia—Prednisone—psoriasis	0.000161	0.00143	CcSEcCtD
Ruxolitinib—Nervous system disorder—Dexamethasone—psoriasis	0.00016	0.00142	CcSEcCtD
Ruxolitinib—Nervous system disorder—Betamethasone—psoriasis	0.00016	0.00142	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Dexamethasone—psoriasis	0.00016	0.00142	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Betamethasone—psoriasis	0.00016	0.00142	CcSEcCtD
Ruxolitinib—Fatigue—Triamcinolone—psoriasis	0.000155	0.00138	CcSEcCtD
Ruxolitinib—Asthenia—Cyclosporine—psoriasis	0.000154	0.00137	CcSEcCtD
Ruxolitinib—Pruritus—Cyclosporine—psoriasis	0.000152	0.00135	CcSEcCtD
Ruxolitinib—Body temperature increased—Hydrocortisone—psoriasis	0.000151	0.00134	CcSEcCtD
Ruxolitinib—Asthenia—Mycophenolate mofetil—psoriasis	0.000151	0.00134	CcSEcCtD
Ruxolitinib—Pruritus—Mycophenolate mofetil—psoriasis	0.000149	0.00132	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000147	0.00131	CcSEcCtD
Ruxolitinib—Malnutrition—Methotrexate—psoriasis	0.000146	0.00129	CcSEcCtD
Ruxolitinib—Body temperature increased—Triamcinolone—psoriasis	0.000142	0.00126	CcSEcCtD
Ruxolitinib—Dizziness—Cyclosporine—psoriasis	0.000142	0.00126	CcSEcCtD
Ruxolitinib—Infection—Prednisone—psoriasis	0.000141	0.00125	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000141	0.00125	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Betamethasone—psoriasis	0.000141	0.00125	CcSEcCtD
Ruxolitinib—Fatigue—Betamethasone—psoriasis	0.000141	0.00125	CcSEcCtD
Ruxolitinib—Fatigue—Dexamethasone—psoriasis	0.000141	0.00125	CcSEcCtD
Ruxolitinib—Nervous system disorder—Prednisone—psoriasis	0.00014	0.00124	CcSEcCtD
Ruxolitinib—Dizziness—Mycophenolate mofetil—psoriasis	0.000139	0.00123	CcSEcCtD
Ruxolitinib—Skin disorder—Prednisone—psoriasis	0.000138	0.00123	CcSEcCtD
Ruxolitinib—Asthenia—Hydrocortisone—psoriasis	0.000137	0.00122	CcSEcCtD
Ruxolitinib—Pruritus—Hydrocortisone—psoriasis	0.000135	0.0012	CcSEcCtD
Ruxolitinib—Headache—Cyclosporine—psoriasis	0.000135	0.0012	CcSEcCtD
Ruxolitinib—Anaemia—Methotrexate—psoriasis	0.000135	0.00119	CcSEcCtD
Ruxolitinib—Headache—Mycophenolate mofetil—psoriasis	0.000132	0.00117	CcSEcCtD
Ruxolitinib—Dizziness—Prednisolone—psoriasis	0.00013	0.00115	CcSEcCtD
Ruxolitinib—Asthenia—Triamcinolone—psoriasis	0.000129	0.00115	CcSEcCtD
Ruxolitinib—Body temperature increased—Betamethasone—psoriasis	0.000129	0.00115	CcSEcCtD
Ruxolitinib—Body temperature increased—Dexamethasone—psoriasis	0.000129	0.00115	CcSEcCtD
Ruxolitinib—Pruritus—Triamcinolone—psoriasis	0.000127	0.00113	CcSEcCtD
Ruxolitinib—Dizziness—Hydrocortisone—psoriasis	0.000127	0.00112	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000123	0.00109	CcSEcCtD
Ruxolitinib—Fatigue—Prednisone—psoriasis	0.000123	0.00109	CcSEcCtD
Ruxolitinib—Headache—Prednisolone—psoriasis	0.000123	0.00109	CcSEcCtD
Ruxolitinib—Headache—Hydrocortisone—psoriasis	0.00012	0.00106	CcSEcCtD
Ruxolitinib—Dizziness—Triamcinolone—psoriasis	0.000119	0.00106	CcSEcCtD
Ruxolitinib—Infection—Methotrexate—psoriasis	0.000118	0.00105	CcSEcCtD
Ruxolitinib—Asthenia—Betamethasone—psoriasis	0.000117	0.00104	CcSEcCtD
Ruxolitinib—Asthenia—Dexamethasone—psoriasis	0.000117	0.00104	CcSEcCtD
Ruxolitinib—Nervous system disorder—Methotrexate—psoriasis	0.000117	0.00103	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Methotrexate—psoriasis	0.000116	0.00103	CcSEcCtD
Ruxolitinib—Pruritus—Dexamethasone—psoriasis	0.000116	0.00102	CcSEcCtD
Ruxolitinib—Pruritus—Betamethasone—psoriasis	0.000116	0.00102	CcSEcCtD
Ruxolitinib—Skin disorder—Methotrexate—psoriasis	0.000116	0.00102	CcSEcCtD
Ruxolitinib—Headache—Triamcinolone—psoriasis	0.000113	0.001	CcSEcCtD
Ruxolitinib—Body temperature increased—Prednisone—psoriasis	0.000113	0.000997	CcSEcCtD
Ruxolitinib—Dizziness—Dexamethasone—psoriasis	0.000108	0.000958	CcSEcCtD
Ruxolitinib—Dizziness—Betamethasone—psoriasis	0.000108	0.000958	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Methotrexate—psoriasis	0.000103	0.00091	CcSEcCtD
Ruxolitinib—Fatigue—Methotrexate—psoriasis	0.000103	0.000909	CcSEcCtD
Ruxolitinib—Headache—Dexamethasone—psoriasis	0.000102	0.000908	CcSEcCtD
Ruxolitinib—Headache—Betamethasone—psoriasis	0.000102	0.000908	CcSEcCtD
Ruxolitinib—Asthenia—Prednisone—psoriasis	0.000102	0.000905	CcSEcCtD
Ruxolitinib—Pruritus—Prednisone—psoriasis	0.000101	0.000893	CcSEcCtD
Ruxolitinib—Dizziness—Prednisone—psoriasis	9.41e-05	0.000834	CcSEcCtD
Ruxolitinib—Body temperature increased—Methotrexate—psoriasis	9.4e-05	0.000834	CcSEcCtD
Ruxolitinib—Headache—Prednisone—psoriasis	8.92e-05	0.00079	CcSEcCtD
Ruxolitinib—Asthenia—Methotrexate—psoriasis	8.53e-05	0.000757	CcSEcCtD
Ruxolitinib—Pruritus—Methotrexate—psoriasis	8.42e-05	0.000746	CcSEcCtD
Ruxolitinib—Dizziness—Methotrexate—psoriasis	7.87e-05	0.000697	CcSEcCtD
Ruxolitinib—Headache—Methotrexate—psoriasis	7.45e-05	0.000661	CcSEcCtD
Ruxolitinib—GRK1—Signaling Pathways—VEGFA—psoriasis	1.03e-05	5.27e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—IL6—psoriasis	1.03e-05	5.27e-05	CbGpPWpGaD
Ruxolitinib—JAK2—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	1.03e-05	5.26e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—NFKB1—psoriasis	1.03e-05	5.25e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—CD4—psoriasis	1.03e-05	5.24e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HLA-A—psoriasis	1.03e-05	5.24e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—STAT3—psoriasis	1.02e-05	5.22e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—IL6—psoriasis	1.02e-05	5.2e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—JUN—psoriasis	1.02e-05	5.19e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—CD4—psoriasis	1.01e-05	5.16e-05	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—CXCL8—psoriasis	1.01e-05	5.15e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HLA-A—psoriasis	9.99e-06	5.09e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	9.97e-06	5.08e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—CXCL8—psoriasis	9.95e-06	5.07e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—JUN—psoriasis	9.89e-06	5.04e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—JUN—psoriasis	9.84e-06	5.01e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—TP53—psoriasis	9.82e-06	5e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CRP—psoriasis	9.81e-06	5e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—NFKB1—psoriasis	9.8e-06	5e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—VEGFA—psoriasis	9.78e-06	4.98e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—STAT3—psoriasis	9.69e-06	4.93e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HLA-A—psoriasis	9.68e-06	4.93e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—TYK2—psoriasis	9.64e-06	4.91e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—JUN—psoriasis	9.61e-06	4.9e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—JUN—psoriasis	9.59e-06	4.89e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—SOCS1—psoriasis	9.57e-06	4.88e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CRP—psoriasis	9.53e-06	4.85e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—NFKB1—psoriasis	9.52e-06	4.85e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—APOE—psoriasis	9.49e-06	4.84e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—LEP—psoriasis	9.49e-06	4.84e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Axon guidance—IL6—psoriasis	9.48e-06	4.83e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—NFKB1—psoriasis	9.47e-06	4.83e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HLA-DRB1—psoriasis	9.4e-06	4.79e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—VEGFA—psoriasis	9.35e-06	4.76e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—STAT3—psoriasis	9.29e-06	4.74e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—TYK2—psoriasis	9.26e-06	4.72e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—STAT3—psoriasis	9.26e-06	4.72e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—NFKB1—psoriasis	9.25e-06	4.71e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CRP—psoriasis	9.24e-06	4.71e-05	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—IL6—psoriasis	9.23e-06	4.7e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—NFKB1—psoriasis	9.23e-06	4.7e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—HLA-A—psoriasis	9.22e-06	4.7e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—CXCL8—psoriasis	9.18e-06	4.68e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—IL6—psoriasis	9.16e-06	4.67e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HLA-DRB1—psoriasis	9.12e-06	4.65e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—JUN—psoriasis	9.07e-06	4.62e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—CXCL8—psoriasis	9.03e-06	4.6e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IFNG—psoriasis	9.02e-06	4.6e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—ICAM1—psoriasis	9.02e-06	4.6e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—IL6—psoriasis	9.01e-06	4.59e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—NFKBIA—psoriasis	8.95e-06	4.56e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—TYK2—psoriasis	8.9e-06	4.53e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—NFKB1—psoriasis	8.86e-06	4.52e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HLA-DRB1—psoriasis	8.85e-06	4.51e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—NFKBIA—psoriasis	8.84e-06	4.51e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—ICAM1—psoriasis	8.76e-06	4.46e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—NFKB1—psoriasis	8.73e-06	4.45e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CD4—psoriasis	8.72e-06	4.44e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—NFKBIA—psoriasis	8.69e-06	4.43e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—APOE—psoriasis	8.61e-06	4.39e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TYK2—psoriasis	8.58e-06	4.37e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—STAT3—psoriasis	8.58e-06	4.37e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—STAT3—psoriasis	8.51e-06	4.34e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—ICAM1—psoriasis	8.49e-06	4.33e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CD8A—psoriasis	8.49e-06	4.33e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—NFKBIA—psoriasis	8.43e-06	4.29e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SOCS1—psoriasis	8.41e-06	4.29e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—TNF—psoriasis	8.38e-06	4.27e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—CD4—psoriasis	8.37e-06	4.27e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—STAT3—psoriasis	8.32e-06	4.24e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—TP53—psoriasis	8.31e-06	4.23e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—NFKB1—psoriasis	8.17e-06	4.16e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HLA-B—psoriasis	8.17e-06	4.16e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SOCS1—psoriasis	8.17e-06	4.16e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—LEP—psoriasis	8.16e-06	4.16e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—APOE—psoriasis	8.16e-06	4.16e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—IL6—psoriasis	8.09e-06	4.12e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—IL6—psoriasis	8.07e-06	4.11e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—CD4—psoriasis	8.05e-06	4.1e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—LEP—psoriasis	8.03e-06	4.09e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—APOE—psoriasis	8.03e-06	4.09e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—NOS2—psoriasis	8.02e-06	4.09e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—IL6—psoriasis	7.94e-06	4.04e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SOCS1—psoriasis	7.92e-06	4.04e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—STAT3—psoriasis	7.84e-06	4e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—TP53—psoriasis	7.81e-06	3.98e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—JUN—psoriasis	7.8e-06	3.97e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NDUFA5—psoriasis	7.78e-06	3.96e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NFKBIA—psoriasis	7.61e-06	3.88e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—IL6—psoriasis	7.6e-06	3.87e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HLA-A—psoriasis	7.57e-06	3.86e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—NFKB1—psoriasis	7.51e-06	3.83e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—JUN—psoriasis	7.49e-06	3.82e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NFKBIA—psoriasis	7.48e-06	3.81e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CXCL8—psoriasis	7.47e-06	3.81e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—VEGFA—psoriasis	7.41e-06	3.78e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—STAT3—psoriasis	7.34e-06	3.74e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—TYK2—psoriasis	7.33e-06	3.73e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—VEGFA—psoriasis	7.27e-06	3.71e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TYK2—psoriasis	7.24e-06	3.69e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CRP—psoriasis	7.22e-06	3.68e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—NFKB1—psoriasis	7.21e-06	3.68e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—IL6—psoriasis	7.18e-06	3.66e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—IL6—psoriasis	7.15e-06	3.64e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—IL6—psoriasis	7.11e-06	3.62e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—TP53—psoriasis	7.06e-06	3.6e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HLA-A—psoriasis	6.99e-06	3.56e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—JUN—psoriasis	6.95e-06	3.54e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HLA-DRB1—psoriasis	6.91e-06	3.52e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—TYK2—psoriasis	6.9e-06	3.52e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IFNG—psoriasis	6.86e-06	3.5e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—CXCL8—psoriasis	6.78e-06	3.45e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—IL6—psoriasis	6.77e-06	3.45e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—STAT3—psoriasis	6.75e-06	3.44e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—NFKB1—psoriasis	6.69e-06	3.41e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IFNG—psoriasis	6.66e-06	3.39e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—ICAM1—psoriasis	6.64e-06	3.38e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CD4—psoriasis	6.63e-06	3.38e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP2S1—psoriasis	6.62e-06	3.37e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—NFKBIA—psoriasis	6.58e-06	3.35e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—APOE—psoriasis	6.52e-06	3.32e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—IL6—psoriasis	6.49e-06	3.31e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—IL6—psoriasis	6.47e-06	3.29e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IFNG—psoriasis	6.46e-06	3.29e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CD4—psoriasis	6.43e-06	3.28e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—TNF—psoriasis	6.35e-06	3.24e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CXCL8—psoriasis	6.31e-06	3.21e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CD4—psoriasis	6.24e-06	3.18e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TYK2—psoriasis	6.23e-06	3.17e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—STAT3—psoriasis	6.23e-06	3.17e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—LEP—psoriasis	6.21e-06	3.16e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—APOE—psoriasis	6.21e-06	3.16e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SOCS1—psoriasis	6.19e-06	3.15e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—IL6—psoriasis	6.15e-06	3.14e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TYK2—psoriasis	6.13e-06	3.12e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NOS2—psoriasis	6.08e-06	3.1e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—VEGFA—psoriasis	6.07e-06	3.09e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—APOE—psoriasis	6.03e-06	3.07e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—LEP—psoriasis	6.03e-06	3.07e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—STAT3—psoriasis	6.01e-06	3.06e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—IL6—psoriasis	6e-06	3.06e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—IL6—psoriasis	5.99e-06	3.05e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—IL6—psoriasis	5.97e-06	3.04e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IL6—psoriasis	5.95e-06	3.03e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CD4—psoriasis	5.94e-06	3.03e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—JUN—psoriasis	5.93e-06	3.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—TYK2—psoriasis	5.9e-06	3.01e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—JUN—psoriasis	5.86e-06	2.99e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—APOE—psoriasis	5.85e-06	2.98e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—LEP—psoriasis	5.85e-06	2.98e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IL6—psoriasis	5.81e-06	2.96e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—IL6—psoriasis	5.79e-06	2.95e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NFKBIA—psoriasis	5.79e-06	2.95e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—JUN—psoriasis	5.76e-06	2.93e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—NFKB1—psoriasis	5.71e-06	2.91e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—CXCL8—psoriasis	5.66e-06	2.88e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—NFKB1—psoriasis	5.64e-06	2.88e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NFKBIA—psoriasis	5.62e-06	2.86e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—JUN—psoriasis	5.59e-06	2.85e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—NFKB1—psoriasis	5.54e-06	2.82e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TP53—psoriasis	5.49e-06	2.8e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IL6—psoriasis	5.48e-06	2.79e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NFKBIA—psoriasis	5.45e-06	2.78e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CXCL8—psoriasis	5.43e-06	2.76e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—TYK2—psoriasis	5.39e-06	2.75e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—NFKB1—psoriasis	5.38e-06	2.74e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CXCL8—psoriasis	5.34e-06	2.72e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—IL6—psoriasis	5.16e-06	2.63e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CXCL8—psoriasis	5.14e-06	2.62e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—STAT3—psoriasis	5.13e-06	2.61e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—IL6—psoriasis	5.13e-06	2.61e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—VEGFA—psoriasis	5.12e-06	2.61e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—IL6—psoriasis	5.07e-06	2.59e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—STAT3—psoriasis	5.07e-06	2.58e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IFNG—psoriasis	5.05e-06	2.57e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—JUN—psoriasis	5.04e-06	2.57e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—STAT3—psoriasis	4.98e-06	2.54e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—TYK2—psoriasis	4.98e-06	2.54e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—JUN—psoriasis	4.96e-06	2.53e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CD4—psoriasis	4.88e-06	2.48e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NFKB1—psoriasis	4.86e-06	2.47e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—STAT3—psoriasis	4.83e-06	2.46e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NFKB1—psoriasis	4.78e-06	2.43e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TYK2—psoriasis	4.74e-06	2.41e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL6—psoriasis	4.71e-06	2.4e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—STAT3—psoriasis	4.6e-06	2.34e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—psoriasis	4.59e-06	2.34e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APOE—psoriasis	4.57e-06	2.33e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—LEP—psoriasis	4.57e-06	2.33e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—IL6—psoriasis	4.53e-06	2.31e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CD4—psoriasis	4.5e-06	2.29e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TYK2—psoriasis	4.46e-06	2.27e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—VEGFA—psoriasis	4.41e-06	2.25e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—JUN—psoriasis	4.36e-06	2.22e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—STAT3—psoriasis	4.36e-06	2.22e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—IL6—psoriasis	4.35e-06	2.22e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—VEGFA—psoriasis	4.33e-06	2.21e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—STAT3—psoriasis	4.29e-06	2.19e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NFKBIA—psoriasis	4.26e-06	2.17e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—NFKB1—psoriasis	4.2e-06	2.14e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL6—psoriasis	4.2e-06	2.14e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CXCL8—psoriasis	4.13e-06	2.1e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CXCL8—psoriasis	4.01e-06	2.04e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CXCL8—psoriasis	3.88e-06	1.98e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—psoriasis	3.87e-06	1.97e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—JUN—psoriasis	3.84e-06	1.95e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL6—psoriasis	3.81e-06	1.94e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—STAT3—psoriasis	3.78e-06	1.92e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—JUN—psoriasis	3.72e-06	1.9e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NFKB1—psoriasis	3.69e-06	1.88e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—JUN—psoriasis	3.61e-06	1.84e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL6—psoriasis	3.58e-06	1.83e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NFKB1—psoriasis	3.58e-06	1.83e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL6—psoriasis	3.54e-06	1.8e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TYK2—psoriasis	3.49e-06	1.78e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—STAT3—psoriasis	3.49e-06	1.78e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL6—psoriasis	3.48e-06	1.77e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NFKB1—psoriasis	3.48e-06	1.77e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL6—psoriasis	3.38e-06	1.72e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—VEGFA—psoriasis	3.35e-06	1.71e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—psoriasis	3.33e-06	1.7e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—STAT3—psoriasis	3.32e-06	1.69e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—psoriasis	3.27e-06	1.67e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—VEGFA—psoriasis	3.25e-06	1.66e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CARM1—psoriasis	3.23e-06	1.65e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—STAT3—psoriasis	3.22e-06	1.64e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IL6—psoriasis	3.21e-06	1.64e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—VEGFA—psoriasis	3.16e-06	1.61e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—STAT3—psoriasis	3.12e-06	1.59e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL6—psoriasis	3.05e-06	1.55e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CXCL8—psoriasis	3.04e-06	1.55e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL6—psoriasis	3e-06	1.53e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL6—psoriasis	2.89e-06	1.47e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—JUN—psoriasis	2.82e-06	1.44e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NFKB1—psoriasis	2.72e-06	1.38e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL6—psoriasis	2.64e-06	1.34e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—psoriasis	2.53e-06	1.29e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—VEGFA—psoriasis	2.47e-06	1.26e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—psoriasis	2.46e-06	1.25e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—STAT3—psoriasis	2.44e-06	1.24e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IL6—psoriasis	2.43e-06	1.24e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—psoriasis	2.38e-06	1.21e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL6—psoriasis	2.32e-06	1.18e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL6—psoriasis	2.25e-06	1.15e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL6—psoriasis	2.18e-06	1.11e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CAT—psoriasis	1.99e-06	1.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—psoriasis	1.86e-06	9.49e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6—psoriasis	1.71e-06	8.69e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOE—psoriasis	1.54e-06	7.87e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPARG—psoriasis	1.34e-06	6.85e-06	CbGpPWpGaD
